Parkinson's disease, Ozempic

Drug Similar to Ozempic Failed to Treat Parkinson’s Disease in a Trial
The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other conditions with newer weight-loss drugs.
Why Did a GLP-1 Receptor Agonist Fail This Parkinson's Trial?
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients. Weekly injections of the GLP-1 receptor agonist exenatide (Byetta, Bydureon) did not slow Parkinson's disease progression or improve symptoms, the phase III Exenatide-PD3 trial showed.
Ozempic-Type Drug Fails To Slow Parkinson’s, Study Finds
WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's disease have taken an hit. A new study found that a drug in the same class called exenatide, marketed as Byetta, had no effect on slowing the disease or easing its symtoms.
GLP-1 drug fails to slow Parkinson's: Study
A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The Lancet,
FDA OKs New Wearable Treatment for Parkinson's Disease
The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced Parkinson's disease, Supernus Pharmaceuticals announced on Tuesday. The wearable device is the first subcutaneous apomorphine infusion device for Parkinson's and provides continuous treatment during the day, Supernus noted.

Daniel Barenboim, Parkinson's disease

She was diagnosed with Parkinson’s at 27. These were her warning signs.
People with early-onset Parkinson’s face challenges different from those with traditional late-onset Parkinson’s.
Psychology Today23h
A Suggested Revolution in Parkinson’s Research
We spend billions searching for the cures to chronic illnesses while neglecting research that could make the daily lives of ...
Medscape7h
Despite Early Promise GLP-1 Disappoints in Parkinson’s Disease
Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...
FDA approves wearable infusion device for advanced Parkinson disease
The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...
Sergey Brin’s $2 Billion Quest To Tackle Parkinson’s, Bipolar Disorder And Now Autism
The Google cofounder has donated more than $1.5 billion to Parkinson’s research. Now, as he takes on autism, he’s also ...
Huntsville biotech firm partnering with Pfizer lands $10 million for Parkinson’s trial
A Huntsville-based biotechnology company has secured $10 million in funding to begin the trial of a new way to deliver medication to advanced Parkinson’s disease patients.
News on 61d
How playing ping pong is helping Tulsans diagnosed with Parkinson's
Doctors and researchers say ping pong can help slow Parkinson's disease. The South County Recreation Center in Bixby hosts ...
Why Phil Parkinson faces a dilemma over his Wrexham squad
Phil Parkinson faces a decision over his Wrexham squad after overseeing a record-breaking January transfer window. Co-owners ...